Since chemotherapy reduces PD-L1 expression in tumor cells for a subset of patients [27], rebiopsy and reassessment of PD-L1 expression may be necessary to determine eligibility for immune checkpoint inhibitor therapy, but so far, there is no standardized PD-L1 testing strategy. This evidence concerns the gene CD274 and neoplasm.